• 
• http://www.nature.com/cgt/
• Editor: Kevin Scanlon, PhD and Robert Sobol, MD
• Volume 16: 12 issues per year
• ISSN: 0929-1903
• EISSN: 1476-5500
• Impact factor : 3.005*
• Impact ranking: 36/144 in Biotechnology & Applied Microbiology; 59/138 in Genetics & Heredity; 60/141 in Oncology; 24/82 in Medicine, Research and Experimental*
• Date Established: 1994

Aims and Scope:
Publishing the latest original research and reviews from laboratory investigations, pre-clinical studies and clinical trials on genetic treatments for cancer, Cancer Gene Therapy is the only journal exclusively covering this subject. The papers published reflect diverse viewpoints from academic, commercial and regulatory perspectives.

Cancer Gene Therapy publishes original papers and review articles on topics such as: RNAi, therapeutics, transgenic stem cell transfer, antisense technology, drug resistance, drug sensitivity, hematopoietic gene transfer, homologous recombination, ribozyme technology, safety testing, vector systems, tumour immunotherapy and tumour suppressors.

Readership: Cancer researchers with an interest in the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene therapy/gene transfer.

Online features and site license access:

• Online archive available back to January 1999.
• A site license provides access to all content published during the supply period. Access is granted to a further rolling four-year archive during the supply period only. Archive content is freely available after five years.
• Indexed in Medline (PubMed), Chemical Abstracts, BIOSIS, Science Citation Index, SciSearch, The Biotechnology Citation Index and Current Contents Clinical Medicine.

*2008 Journal Citation Report (Thomson Reuters, 2009)